Weight Loss Drugs (BK2152) Stock Price, News, Quotes-Moomoo

Weight Loss Drugs Watchlist

GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.

1749.614
-9.766-0.56%

Close May 17 16:00 ET

1759.340High1742.756Low

Constituent Stocks: 7Top Rising: GPCR+0.75%

Intraday

Constituent Stocks

SymbolStock Name

Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

GPCRStructure Therapeutics

36.1500.270+0.75%434.24K15.61M35.88035.88036.75035.2901.69B1.39B46.62M38.40M+0.92%-7.99%-0.58%-11.89%-29.83%+49.13%-11.31%--1.13%LossLoss4.07%Biotechnology

LLYEli Lilly and Co

770.000-1.120-0.15%1.67M1.29B772.890771.120774.870767.100731.81B730.11B950.41M948.20M+1.49%+4.95%+6.20%+0.22%+28.54%+75.36%+32.55%0.61%0.18%113.40132.761.01%Drug Manufacturers - General

AMGNAmgen

312.470-2.250-0.71%1.97M616.79M315.280314.720315.280310.370167.62B167.12B536.43M534.84M+1.46%+1.09%+17.02%+10.35%+19.47%+44.23%+10.12%2.77%0.37%44.6425.021.56%Drug Manufacturers - General

NVONovo-Nordisk A/S

131.890-1.150-0.86%2.59M341.00M131.940133.040132.086130.850587.72B420.70B4.46B3.19B+2.70%+7.18%+7.48%+6.68%+25.98%+56.53%+28.41%1.04%0.08%45.4848.630.93%Biotechnology

PFEPfizer

28.640-0.280-0.97%26.11M747.57M28.89528.92028.91028.510162.29B162.04B5.67B5.66B+2.25%+4.54%+11.82%+5.52%-3.25%-17.76%+2.50%5.76%0.46%Loss77.411.38%Drug Manufacturers - General

VKTXViking Therapeutics

67.000-2.060-2.98%4.15M283.02M69.99069.06071.09066.6807.39B6.99B110.27M104.36M-9.02%-12.95%+5.64%+87.89%+445.60%+191.68%+260.02%--3.98%LossLoss6.39%Biotechnology

ALTAltimmune

8.010-0.890-10.00%4.04M32.85M8.7908.9008.8057.860567.93M563.43M70.90M70.34M+10.94%+9.73%+15.92%-9.70%+185.05%+78.40%-28.80%--5.75%LossLoss10.62%Biotechnology

News

Comments

Moomoo AI

Jan 10 14:33

Goldman Sachs likens obesity drugs to early Amazon and Apple, suggesting they may expand into unanticipated areas. With potential customers exceeding 100 million in the U.S., the market for these treatments is vast. Investors are urged to consider Lilly call options expiring in January 2025.

Eli Lilly Could Be the Next Apple Stock. It Still Looks Cheap. -- Barrons.com

Moomoo AI

Nov 27, 2023 23:38

Market anticipation grows over imminent competition between Eli Lilly and Novo Nordisk with Zepbound's FDA approval. Mounjaro's superior weight loss efficacy could positively impact Eli Lilly's market performance.

Eli Lilly's Mounjaro Three Times More Effective Than Ozempic for Weight Loss, Real-world Study Finds

Ava Quinn

Oct 17, 2023 11:12

The new favorite of US stocks

The US stock market's excitement about weight loss drugs/GLP-1 has now exceeded the AI craze that will dominate the first half of 2023.
$Novo-Nordisk A/S(NVO.US)$ $Weight Loss Drugs(LIST2152.US)$ $Eli Lilly and Co(LLY.US)$ $S&P 500 Index(.SPX.US)$ $E-mini NASDAQ 100 Futures(JUN4)(NQmain.US)$ $NVIDIA(NVDA.US)$ $Microsoft(MSFT.US)$ $Meta Platforms(META.US)$

Noah Johnson

Oct 11, 2023 11:27

ColumnsFirst-Mover Advantage: Novo Nordisk and Eli Lilly Have at Least Four-Year Monopoly Periods Ahead

1.The success of Wegovy is just the beginning for GLP-1 medications.
Since its approval in June 2021, the obesity treatment market has undergone a significant transformation. Wegovy, as a GLP-1 medication, has achieved tremendous success. Its effectiveness surpasses that of previously marketed weight-loss drugs, and it is also considered safer.
According to Barclays' predictions, there is still enorm...

Weight-loss drugmakers report strong earnings: Boon or bane?

Noah Johnson

Oct 9, 2023 10:48

ColumnsAnother Endorsement by Musk: Is the Weight Loss Supplement Truly Miraculous?

1.The global market space for weight-loss drugs exceeds 100 billion dollars.
Wegovy, which has sparked discussions on social media, is a GLP-1 receptor agonist medication. GLP-1 drugs have now become a goldmine for pharmaceutical giants Novo Nordisk and Eli Lilly, propelling Novo Nordisk to become the most valuable company in Europe, surpassing LVMH Group.
It is said that by sticking to a weekly injection, weight can be...

Weight-loss drugmaker surpasses LVMH: What's your thought?